Nonsterile Preparations - NAPLEX

1. A 78-year-old female (weight 55 kg) with heart failure is prescribed potassium chloride oral solution $20\ \text{mEq}/15\ \text{mL}$, take $15\ \text{mL}$ daily. She reports nausea and poor adherence due to the salty taste and asks the pharmacist to add flavoring to improve palatability. The product will be dispensed as an oral solution (not a suspension). Which ingredient should be added to achieve the desired flavor?
   Answer: A small amount of a commercially available oral flavor concentrate (e.g., cherry) compatible with aqueous solutions This question tests knowledge of flavoring aqueous oral solutions to improve palatability while maintaining pharmaceutical elegance. The elderly patient with heart failure finds potassium chloride's salty taste nauseating, which affects adherence to this important electrolyte replacement therapy. The correct answer (A) recommends using a small amount of commercially available oral flavor concentrate compatible with aqueous solutions, which effectively masks unpleasant tastes without compromising the solution's properties. Option B's alcohol-based peppermint oil could cause irritation and is inappropriate for elderly patients. Option C's calcium carbonate would create chemical incompatibility and precipitation with potassium chloride. Option D's undissolved sucrose crystals would convert the solution to a suspension, changing the dosage form. The key principle is that flavoring agents for oral solutions must be water-compatible, used in appropriate concentrations, and not alter the physical or chemical properties of the preparation.
2. A 28-year-old female (weight 70 kg) with chronic hand eczema is prescribed a custom topical preparation due to inadequate response to commercial strengths. Prescription: clobetasol propionate 0.025% ointment, apply twice daily for 14 days, dispense 45 g. The pharmacy has clobetasol propionate 0.05% ointment available and will dilute it with ointment base to achieve 0.025%. What is the appropriate compounding procedure for this medication?
   Answer: Mix 1 part of 0.05% ointment with 1 part of plain ointment base using geometric dilution until uniform This question assesses understanding of dilution calculations for topical corticosteroid preparations. The patient needs clobetasol 0.025% ointment, diluted from the available 0.05% strength for chronic hand eczema. The correct answer (A) uses equal parts (1:1 ratio) of 0.05% ointment and plain base, which mathematically yields 0.025% concentration (0.05% ÷ 2 = 0.025%). Option B's 1:3 ratio would yield 0.0125% (0.05% ÷ 4), which is too dilute. Option C incorrectly suggests adding water to an ointment, which would destabilize the oleaginous base. Option D's heating method is dangerous and would not achieve the desired concentration. The dilution principle for percentage strengths is: C1V1 = C2V2, and when mixing equal volumes of drug-containing base with plain base, the concentration is halved.
3. A 82-year-old male (weight 72 kg) takes an oral iron solution and reports metallic taste leading to missed doses. The prescriber requests: "Flavor ferrous sulfate oral solution; dispense 240 mL; maintain the same concentration." Which ingredient should be added to achieve the desired flavor?
   Answer: A compatible flavor such as grape or cherry plus a sweetener, considering potential tooth staining counseling This question tests flavoring approaches for metallic-tasting oral solutions to improve compliance. The key patient-specific factor is the elderly patient's missed doses due to ferrous sulfate's metallic taste. Option A is the best choice as compatible flavors like grape with sweeteners mask metallic notes and counsel on staining. Option B is incorrect as charcoal binds the drug; option C is suboptimal with pH changes risking instability; option D is wrong due to essential oil toxicity. Distractors introduce incompatibilities. A compounding pearl is to use fruit flavors for metallic tastes and warn about dental effects. Evaluate patient age and comorbidities when selecting flavoring agents for long-term use.
4. A 9-year-old male (weight 30 kg) requires baclofen for spasticity but cannot swallow tablets. Prescription: "Baclofen 1 mg/mL oral suspension; quantity 300 mL; compound from tablets." Which is the appropriate compounding procedure for this medication?
   Answer: Triturate tablets to a fine powder, levigate with a small amount of vehicle to form a smooth paste, then geometrically add vehicle and q.s. to final volume This question tests appropriate compounding procedures for oral suspensions from tablets, including trituration and geometric dilution. The key compounding factor is baclofen's need for fine dispersion to ensure dose uniformity. Option A is the best choice as trituration, levigation, and geometric addition create a stable, uniform suspension. Option B is incorrect without agitation, leading to incomplete dispersion; option C is suboptimal as heat can degrade baclofen; option D is wrong as oil-based without suspending agents risks separation. Distractors highlight improper techniques. A compounding pearl is to always triturate tablets finely before suspension to minimize particle size variability. For pediatric formulations, calibrate volumes precisely and add flavoring to improve adherence.
5. A 38-year-old male (weight 82 kg) with psoriasis needs a compounded topical due to sensitivity to commercial products. Prescription: "Salicylic acid 3% in ointment; quantity 60 g; apply to plaques once daily." He has a documented allergy to salicylates (angioedema). How should the pharmacist adjust the formulation for this patient?
   Answer: Clarify with the prescriber and recommend an alternative keratolytic/non-salicylate option due to salicylate allergy This question tests formulation adjustments for compounded topicals in patients with allergies, focusing on salicylate avoidance. The key patient-specific factor is the salicylate allergy (angioedema), which contraindicates salicylic acid. Option B is the best choice as clarifying with the prescriber and suggesting alternatives prioritizes safety. Option A is incorrect as topical salicylates can cause systemic reactions; option C is suboptimal without consultation; option D is wrong and could exacerbate allergy. Distractors ignore allergy risks. A compounding pearl is to treat salicylate allergies as contraindications for related compounds. Use a framework: confirm allergy details, evaluate ingredients, and collaborate with prescribers for safe alternatives.
6. A 6-year-old female (weight 20 kg) with a urinary tract infection cannot swallow capsules. Prescription: nitrofurantoin oral suspension $25\ \text{mg}/5\ \text{mL}$, take $10\ \text{mL}$ by mouth every 6 hours for 7 days, dispense 300 mL. The pharmacist compounds the suspension from nitrofurantoin capsules and an oral suspending vehicle. Which compounding error could compromise the preparation's stability?
   Answer: Using tap water as the sole vehicle and omitting a structured suspending agent, leading to caking and non-uniform dosing This question tests identification of compounding errors that compromise suspension stability. The pediatric patient needs nitrofurantoin suspension for UTI treatment, compounded from capsules. The correct answer (C) identifies using tap water without a structured suspending agent as the critical error, leading to rapid settling, caking, and non-uniform dosing of this antimicrobial. Option A's amber packaging protects from light degradation. Option B's USP-compliant beyond-use dating ensures safety. Option D's geometric dilution technique ensures proper drug distribution. The key concept is that suspensions require appropriate suspending vehicles (not just water) to maintain uniform drug distribution throughout the beyond-use period, ensuring each dose contains the intended amount of medication for effective antimicrobial therapy.
7. A 79-year-old female (weight 55 kg) takes lactulose solution but refuses it due to sweetness and aftertaste; the prescriber requests flavoring to improve adherence while keeping the same concentration and dose. Which ingredient should be added to achieve the desired flavor?
   Answer: A compatible flavoring agent (for example, citrus) and, if needed, a small amount of acidulant per flavor system guidance This question tests flavoring techniques for overly sweet oral solutions to enhance palatability without compromising stability. The key patient-specific factor is the elderly patient's refusal of lactulose due to excessive sweetness. Option A is the best choice as compatible flavors like citrus with acidulants reduce perceived sweetness per flavoring guidelines. Option B is incorrect as calcium carbonate may cause incompatibilities; option C is suboptimal with high essential oil risks; option D is wrong as propylene glycol dilution could alter osmolarity. Distractors introduce unsafe or incompatible agents. A compounding pearl is to balance flavors with the drug's profile, using acidulants for sweet tastes. Always evaluate excipient compatibility and patient age when flavoring chronic therapies.
8. A 10-year-old female (weight 32 kg) needs levetiracetam but cannot swallow tablets. Prescription: "Levetiracetam 100 mg/mL oral suspension; quantity 150 mL; compound from tablets; label with storage and beyond-use date." Which compounding error could compromise the preparation's stability?
   Answer: Dispensing without a tight, child-resistant closure, increasing contamination risk This question tests identification of compounding errors in oral suspensions, focusing on packaging for contamination prevention. The key compounding factor is levetiracetam's aqueous suspension needing secure closures for safety. Option C is the best choice as lacking child-resistant closures increases contamination and access risks. Option A is not an error but correct vehicle use; option B is standard dilution; option D is appropriate labeling. Distractors are proper steps. A compounding pearl is to always use tight, child-resistant containers for pediatric orals. Assign BUDs conservatively for aqueous formulations to mitigate microbial risks.
9. A 58-year-old male (weight 85 kg) with chronic pain is prescribed a compounded topical due to need for a custom concentration: "Ketamine 10% topical cream; quantity 30 g; apply to affected area twice daily." He has no allergies. Which compounding error could compromise the preparation's stability?
   Answer: Failing to mix thoroughly and dispensing with visible drug clumps, leading to nonuniform dosing This question tests identification of compounding errors in topical creams, emphasizing thorough mixing for dose uniformity. The key compounding factor is ketamine's need for even distribution to avoid inconsistent application. Option C is the best choice as inadequate mixing leads to clumps and nonuniform dosing. Option A is not an error but correct dilution; option B is standard selection; option D is appropriate packaging. Distractors represent proper practices. A compounding pearl is to mix semisolids until visually uniform and test for homogeneity if needed. For pain topicals, ensure glove use during application to prevent systemic absorption.
10. A 6-year-old female (weight 20 kg) needs spironolactone for heart failure but cannot swallow tablets. Prescription: "Compound spironolactone 5 mg/mL oral suspension from tablets; quantity 200 mL; add flavoring as needed." Which compounding error could compromise the preparation's stability?
    Answer: Leaving the compounded suspension in an open beaker overnight before bottling to allow air bubbles to dissipate This question tests identification of compounding errors in preparing oral suspensions from tablets, focusing on techniques that affect stability. The key compounding factor is spironolactone's hydrophobicity, requiring proper dispersion for uniformity. Option B is the best choice as leaving the suspension in an open beaker allows evaporation and contamination, compromising stability. Option A is not an error but a correct technique to minimize loss; option C is standard geometric dilution; option D is appropriate packaging and labeling. Distractors represent proper steps, highlighting the error in exposure. A compounding pearl is to minimize air exposure during compounding to prevent oxidation and microbial ingress. For suspensions, use a closed system and assign BUDs based on the drug's sensitivity to light, air, and temperature.
11. A 5-year-old male (weight 19 kg) needs gabapentin but cannot swallow capsules. Prescription: "Gabapentin 50 mg/mL oral suspension; quantity 100 mL; compound from capsules; label with beyond-use date." Which is the most important counseling point for this compounded medication?
    Answer: Shake well before each dose and use an oral syringe for measuring; do not use a household spoon This question tests counseling points for compounded oral suspensions, focusing on administration techniques for accurate dosing. The key patient-specific factor is the 5-year-old child's inability to swallow capsules, necessitating a suspension. Option A is the best choice as shaking ensures uniformity and oral syringes provide precise pediatric dosing. Option B is incorrect as crushing in mouth is unnecessary and risky; option C is suboptimal without evidence of food inactivation; option D is wrong as abrupt stopping can cause withdrawal. Distractors promote unsafe practices. A compounding pearl is to recommend calibrated devices over household spoons for liquids. Counsel on storage and shaking to maintain suspension efficacy throughout therapy.
12. A 8-year-old male (weight 27 kg) needs carvedilol but cannot swallow tablets. Prescription: "Carvedilol 1 mg/mL oral suspension; quantity 150 mL; compound from tablets; label with beyond-use date." Which is the appropriate compounding procedure for this medication?
    Answer: Crush tablets, disperse in a small portion of vehicle to form a smooth paste, then geometrically add vehicle and q.s. to final volume in a calibrated container This question tests appropriate compounding procedures for oral suspensions from tablets, including crushing and geometric dilution. The key compounding factor is carvedilol's need for fine dispersion to prevent settling. Option A is the best choice as crushing, pasting, and geometric addition ensure uniformity in a calibrated container. Option B is incorrect without suspending agents; option C is suboptimal without agitation; option D is wrong as form change requires consultation. Distractors promote instability. A compounding pearl is to use calibrated bottles for accurate volume in suspensions. For beta-blockers, counsel on consistent dosing and monitor for adherence in pediatrics.
13. A 3-year-old male (weight 15 kg) needs furosemide but cannot swallow tablets. Prescription: "Furosemide 2 mg/mL oral suspension; quantity 120 mL; compound from tablets." Which compounding error could compromise the preparation's stability?
    Answer: Using a clear container and storing in direct sunlight on the windowsill to simplify caregiver access This question tests identification of compounding errors in light-sensitive oral suspensions, emphasizing storage conditions. The key compounding factor is furosemide's photodegradation, requiring protection from light. Option C is the best choice as clear containers and sunlight exposure accelerate degradation. Option A is not an error but correct amber use; option B is standard BUD assignment; option D is appropriate shaking. Distractors represent proper practices. A compounding pearl is to store photosensitive drugs in light-resistant containers away from direct light. Use a framework: assess drug sensitivities, recommend storage, and educate caregivers on stability factors.
14. A 2-year-old female (weight 11 kg) needs enalapril for hypertension but cannot swallow tablets. Prescription: "Enalapril 1 mg/mL oral suspension; quantity 100 mL; compound from tablets; provide storage and beyond-use date." Which is the most important counseling point for this compounded medication?
    Answer: Shake well before each dose, measure with an oral syringe, and keep out of reach of children This question tests knowledge of appropriate counseling for compounded nonsterile oral suspensions, particularly those prepared from tablets for pediatric use. The key factors include the patient's young age (2 years old), the need for accurate dosing in hypertension management, and the physical properties of a suspension that may settle over time. Choice B is the best counseling point because shaking ensures uniform distribution of the active ingredient, an oral syringe provides precise measurement for the small 1 mg/mL doses needed for an 11 kg child, and keeping it out of reach prevents accidental ingestion. Choice A is incorrect as bathroom storage exposes the medication to humidity, which can degrade stability and promote microbial growth, while choice C is suboptimal because antihypertensive therapy should not be intermittently stopped without medical advice, risking rebound hypertension. Choice D is inappropriate due to potential incompatibility of enalapril with milk proteins, which could reduce bioavailability, and diluting in a full bottle may lead to incomplete dosing if not fully consumed. A key compounding pearl is to always emphasize shaking suspensions and using calibrated devices for accuracy in pediatric patients. When counseling on compounded products, reinforce adherence to beyond-use dates and storage conditions to maintain efficacy and safety.
15. A 28-year-old male (weight 75 kg) with localized neuropathic pain requests a compounded topical due to inadequate relief from OTC products. Prescription: "Lidocaine 5% and ketoprofen 10% topical cream; quantity 60 g; apply to affected area three times daily." He has a known aspirin allergy (urticaria). How should the pharmacist adjust the formulation for this patient?
    Answer: Clarify with the prescriber because ketoprofen is an NSAID and may pose risk in aspirin-allergic patients; consider a non-NSAID alternative This question tests formulation adjustments for compounded topicals in patients with allergies, focusing on NSAID cross-reactivity. The key patient-specific factor is the aspirin allergy (urticaria), which may extend to other NSAIDs like ketoprofen. Option C is the best choice as it prompts clarification with the prescriber due to potential cross-reactivity risks, suggesting safer non-NSAID alternatives. Option A is incorrect as ketoprofen can cross-react with aspirin; option B is suboptimal without prescriber input and diclofenac also poses risks; option D is wrong as adding salicylate could worsen the allergy. Distractors ignore allergy safety protocols. A compounding pearl is to screen for cross-reactive ingredients and consult prescribers for alternatives in allergic patients. Use a framework: identify allergen, evaluate formulation components, and prioritize patient safety over proceeding as written.
16. A 12-year-old male (weight 40 kg) needs clonidine for ADHD-related sleep issues but cannot swallow tablets. Prescription: "Clonidine 0.02 mg/mL oral suspension; quantity 120 mL; compound from tablets; label with beyond-use date." Which compounding error could compromise the preparation's stability?
    Answer: Assigning a beyond-use date of 90 days for a water-containing oral suspension stored at room temperature This question tests identification of compounding errors in oral suspensions, particularly beyond-use date assignment for stability and safety. The key compounding factor is preparing clonidine suspension from tablets for a child unable to swallow solids. Option C is the best choice as assigning a 90-day beyond-use date at room temperature exceeds USP <795> guidelines for aqueous orals, risking microbial growth and degradation. Option A is not an error but proper vehicle selection and shaking; option B is a standard trituration technique; option D is appropriate labeling for uniformity and dosing accuracy. Distractors like A, B, and D are correct practices, emphasizing the need to spot BUD errors. A compounding pearl is that nonsterile aqueous oral suspensions have a maximum 14-day refrigerated BUD unless extended by testing. Use a decision framework: assess water content, storage temperature, and drug stability data before assigning BUDs.
17. A 66-year-old female (weight 58 kg) is prescribed an oral solution of a bitter medication and requests flavoring to improve adherence. Prescription: "Flavor the existing oral solution; dispense 180 mL; do not change the active drug concentration." Which ingredient should be added to achieve the desired flavor?
    Answer: A compatible sweetener (for example, sucralose) and a flavoring agent selected to match the medication's taste profile This question tests flavoring methods for bitter oral solutions, focusing on compatible additives for palatability. The key patient-specific factor is the elderly patient's need for adherence to a bitter medication. Option A is the best choice as sweeteners with matched flavors effectively mask bitterness without stability issues. Option B is incorrect with incompatible viscosity changes; option C is suboptimal as anesthetics are unsafe; option D is wrong with excessive acid risking degradation. Distractors pose risks. A compounding pearl is to test flavor compatibility in small batches. Consider patient preferences and drug interactions when enhancing taste for chronic therapies.
18. A 40-year-old female (weight 68 kg) with neuropathic pain is prescribed compounded gabapentin capsules because she has a documented allergy to tartrazine (FD&C Yellow No. 5) found in some commercial products. Prescription: gabapentin 300 mg capsules, take 1 capsule by mouth three times daily, dispense 90 capsules. The pharmacist will compound using a dye-free capsule shell and excipients. What is the appropriate compounding procedure for this medication?
    Answer: Weigh and triturate gabapentin powder, calculate and add a suitable filler to achieve target capsule fill weight, blend uniformly, and encapsulate using dye-free capsules This question evaluates proper capsule compounding technique for patients with dye allergies. The patient needs gabapentin capsules without tartrazine (Yellow No. 5), requiring dye-free compounding. The correct answer (A) describes the proper technique: weighing drug, calculating and adding filler for appropriate capsule fill volume, blending uniformly, and using dye-free capsules. Option B's water-filled capsules would dissolve the gelatin shells and create an unusable product. Option C dangerously suggests using colored capsules despite the dye allergy. Option D's direct filling without blending risks poor content uniformity, especially critical for a controlled substance like gabapentin. The compounding principle is that proper powder blending with appropriate fillers ensures content uniformity in capsules, and all components including capsule shells must be screened for patient allergens.
19. A 45-year-old male (weight 82 kg) with hypothyroidism needs levothyroxine capsules compounded because he has a severe lactose allergy and reacts to lactose-containing commercial tablets. Prescription: levothyroxine sodium 50 mcg capsules, take 1 capsule by mouth daily, dispense 60 capsules. The pharmacy will compound using lactose-free excipients. How should the pharmacist adjust the formulation for this patient?
    Answer: Use a lactose-free filler such as microcrystalline cellulose and consider adding a small amount of colloidal silicon dioxide to improve uniformity This question evaluates formulation adjustments for patients with excipient allergies, specifically lactose intolerance in levothyroxine capsules. The patient has severe lactose allergy and reacts to commercial tablets containing lactose as a filler. The correct answer (B) recommends using lactose-free fillers like microcrystalline cellulose with colloidal silicon dioxide to improve powder flow and ensure content uniformity in these low-dose capsules. Option A incorrectly suggests using lactose, which would trigger the patient's allergy. Option C's dose adjustment is inappropriate and dangerous, as thyroid hormone requires precise dosing. Option D's aqueous solution would be unstable and the 90-day beyond-use date is incorrect for preservative-free aqueous preparations. The compounding principle is that excipient selection must consider patient allergies while maintaining proper pharmaceutical properties, and flow agents like silicon dioxide are crucial for uniform distribution of potent drugs in capsules.
20. A 35-year-old female (weight 68 kg) with melasma is prescribed a custom topical preparation due to lack of a suitable commercial strength: "Hydroquinone 6% cream; apply thin layer nightly; quantity 30 g." She has no known allergies. What is the appropriate compounding procedure for this medication?
    Answer: Geometrically incorporate hydroquinone powder into the cream base using levigation with a small amount of compatible liquid, then q.s. to 30 g This question tests appropriate compounding procedures for topical creams, including geometric incorporation and levigation for uniform dispersion. The key patient-specific factor is the need for a 6% hydroquinone strength not commercially available, with no allergies noted. Option B is the best choice as geometric incorporation with levigation ensures even distribution and minimizes clumping in the cream base. Option A is incorrect due to lack of levigation, risking poor dispersion; option C is suboptimal as high heat can degrade hydroquinone and rapid cooling may cause crystallization; option D is wrong because creams can suspend hydroquinone effectively, and alcohol gels are not required. Distractors highlight improper techniques that compromise homogeneity. A compounding pearl is to use geometric dilution for all powders in semisolids to achieve uniformity. Always wear PPE and work in a well-ventilated area when handling potent skin-lightening agents like hydroquinone.

Start this quiz